Buscar
Xencor Inc
XNCRAñadir a la lista de seguimiento
11.220USD
-0.660-5.56%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
831.87MCap. mercado
PérdidaP/E TTM
Más Datos de Xencor Inc Compañía
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Información de Xencor Inc
Símbolo de cotizaciónXNCR
Nombre de la empresaXencor Inc
Fecha de salida a bolsaDec 03, 2013
Director ejecutivoDahiyat (Bassil I)
Número de empleados250
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 03
Dirección465 N. Halstead St.
CiudadPASADENA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91107
Teléfono16263055900
Sitio Webhttps://xencor.com/
Símbolo de cotizaciónXNCR
Fecha de salida a bolsaDec 03, 2013
Director ejecutivoDahiyat (Bassil I)
Ejecutivos de Xencor Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
Otro
46.52%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
Otro
46.52%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
54.03%
Investment Advisor/Hedge Fund
32.00%
Hedge Fund
18.37%
Venture Capital
7.44%
Research Firm
5.09%
Individual Investor
1.17%
Pension Fund
0.85%
Bank and Trust
0.38%
Insurance Company
0.03%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q4
364
84.79M
119.03%
--
2026Q1
448
94.73M
127.77%
+2.75K
2025Q4
446
84.30M
118.05%
-5.40M
2025Q3
434
80.43M
112.65%
-6.04M
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
10.66M
14.54%
+80.73K
+0.76%
Dec 31, 2025
PRIMECAP Management Company
10.22M
13.93%
-456.70K
-4.28%
Dec 31, 2025
BVF Partners L.P.
7.13M
9.73%
+2.51M
+54.43%
Dec 31, 2025
RTW Investments L.P.
6.78M
9.24%
+556.41K
+8.94%
Dec 31, 2025
RA Capital Management, LP
4.74M
6.46%
+4.74M
--
Mar 23, 2026
State Street Investment Management (US)
4.51M
6.15%
+833.42K
+22.69%
Dec 31, 2025
EcoR1 Capital, LLC
3.25M
4.43%
-2.89M
-47.09%
Dec 31, 2025
TCG Crossover Management, LLC
2.45M
3.34%
--
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
2.09%
Tema Oncology ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
Invesco NASDAQ Future Gen 200 ETF
0.97%
Invesco S&P SmallCap Health Care ETF
0.64%
ALPS Medical Breakthroughs ETF
0.43%
State Street SPDR S&P Biotech ETF
0.33%
Inspire Small/Mid Cap ESG ETF
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción2.09%
Tema Oncology ETF
Proporción1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.06%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.97%
Invesco S&P SmallCap Health Care ETF
Proporción0.64%
ALPS Medical Breakthroughs ETF
Proporción0.43%
State Street SPDR S&P Biotech ETF
Proporción0.33%
Inspire Small/Mid Cap ESG ETF
Proporción0.3%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.15%
ProShares Ultra Nasdaq Biotechnology
Proporción0.15%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
